However, the health spending watchdog, the National Institute of Health and Care Excellence (NICE), said that it \u201cdoes not currently demonstrate value for the NHS\u201d.<\/p>\n
It is the second time a new Alzheimer\u2019s treatment has been rejected by NICE in a matter of months.<\/p>\n
Manufactured by pharmaceutical giant Eli Lilly, donanemab, also known as Kisunla, is a targeted antibody drug that slows down the early stages of Alzheimer\u2019s.<\/p>\n
<\/div>\n
Along with another new Alzheimer\u2019s drug called lecanemab, it has been billed as a huge step forward in research because they both target a known cause of the disease \u2013 instead of just treating the symptoms.<\/p>\n
Commenting on new draft guidance rejecting the drug, Helen Knight from NICE said: \u201cFor NICE to be able to approve a medicine for use in the NHS it must provide additional benefits to patients, and it must also represent a good use of NHS resources and taxpayers\u2019 money.<\/p>\n
\u201cOur independent committee looked at all the available evidence, including the benefits for carers.<\/p>\n
\u201cThis shows donanemab could slow down cognitive decline by four to seven months, but this is just not enough benefit to justify the additional cost to the NHS.<\/p>\n
\u201cThe cost-effectiveness estimate for donanemab is five to six times above what NICE normally considers an acceptable use of NHS resources.<\/p>\n
\u201cI know this will be disappointing news, but this is an emerging field of medicine and there are other treatments being developed.\u201d<\/p>\n
In August, the Medicines and Healthcare products Regulatory Agency (MHRA) said that lecanemab was efficient in slowing down Alzheimer\u2019s and made it the first drug of its kind to be licensed for use in England.<\/p>\n
However, NICE similarly said that lecanemab would not be rolled out across the NHS because the benefits are \u201cjust too small to justify the significant cost\u201d.<\/p>\n
Concerns have been raised that the decision would lead to a two-tier system for Alzheimer\u2019s patients \u2013 with those able to afford the drug able to access it privately while others who rely on NHS care were left without.<\/p>\n
Hilary Evans-Newton, chief executive at Alzheimer\u2019s Research UK, said: \u201cToday\u2019s announcement marks another frustrating setback for people affected by Alzheimer\u2019s disease.<\/p>\n
\u201cWe finally have two new treatments licensed in Britain for Alzheimer\u2019s, but it\u2019s incredibly disappointing that NHS patients won\u2019t receive them.\u201d<\/p>\n
Professor Fiona Carragher, chief policy and research officer at Alzheimer\u2019s Society, said: \u201cDisease-modifying therapies like donanemab and lecanemab offer a new horizon of hope in the fight against dementia.<\/p>\n
\u201cMHRA\u2019s approval of donanemab marks another milestone in this journey, but it comes alongside a draft NICE decision not to recommend donanemab for use on the NHS. While this is disheartening, we respect the decision of the regulator.\u201d<\/p>\n
<\/em> <\/p>\nThis post appeared first on sky.com<\/div>\n","protected":false},"excerpt":{"rendered":"
A new pioneering Alzheimer\u2019s drug has been rejected for widespread use in the NHS in…<\/p>\n","protected":false},"author":0,"featured_media":5546,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-5545","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tech-news"],"_links":{"self":[{"href":"https:\/\/tradetrovex.com\/index.php\/wp-json\/wp\/v2\/posts\/5545","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tradetrovex.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tradetrovex.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/tradetrovex.com\/index.php\/wp-json\/wp\/v2\/comments?post=5545"}],"version-history":[{"count":0,"href":"https:\/\/tradetrovex.com\/index.php\/wp-json\/wp\/v2\/posts\/5545\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tradetrovex.com\/index.php\/wp-json\/wp\/v2\/media\/5546"}],"wp:attachment":[{"href":"https:\/\/tradetrovex.com\/index.php\/wp-json\/wp\/v2\/media?parent=5545"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tradetrovex.com\/index.php\/wp-json\/wp\/v2\/categories?post=5545"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tradetrovex.com\/index.php\/wp-json\/wp\/v2\/tags?post=5545"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}